

# **NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

## **HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

### **Equality impact assessment– Guidance development**

#### **STA Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by birch tree pollen**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### **Final Draft Guidance**

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?
N/A

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?
No other issues raised.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?
No other issues identified.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No.

7. Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?

N/A

**Approved by Associate Director:** Emily Crowe

**Date:** 26/06/2025